Vergoeding 2015-2019 voor ATC-subgroep G04BD : Middelen bij urge-incontinentie
- Raming voor de totale Zvw-populatie
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| G04BD02 Flavoxaat (Urispas ®) | 130.550 | 124.780 | 108.370 | 93.555 | 83.785 |
| G04BD04 Oxybutynine (Dridase ®) | 1.234.200 | 572.340 | 569.570 | 611.500 | 1.524.900 |
| G04BD07 Tolterodine (Detrusitol ®) | 537.470 | 474.630 | 459.730 | 534.560 | 681.460 |
| G04BD08 Solifenacine (Vesicare ®) | 13.283.900 | 13.485.600 | 12.889.000 | 12.466.200 | 11.703.000 |
| G04BD10 Darifenacine (Emselex ®) | 1.799.100 | 1.736.000 | 1.490.200 | 1.323.500 | 1.269.700 |
| G04BD11 Fesoterodine (Toviaz ®) | 1.542.900 | 1.477.100 | 1.373.600 | 1.273.700 | 1.272.100 |
| G04BD12 Mirabegron (Betmiga ®) | 2.990.000 | 3.548.700 | 4.349.300 | 5.113.800 | 5.692.700 |
| Totaal | 21.518.120 | 21.419.150 | 21.239.770 | 21.416.815 | 22.227.645 |